SBC celebrates its fifth birthday with new publication to showcase its

Five Years of Innovation with Impact’ highlights SBC influence on UK biotech sector

Stevenage, UK, September 6 2017 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, is marking its fifth birthday with the launch of an activity review, ‘Five Years of Innovation with Impact‘. Following developments since 2011, the publication draws a vibrant picture of the UK’s first open innovation biomedical campus through figures, case studies and testimonials. The report, which is available below, shows how SBC has delivered on its vision of becoming a world-leading hub for life sciences activity.

Highlights of the report include case studies of the University of Cambridge innovation hub at SBC, the open innovation neurodegenerative disease challenge, and cell and gene therapy activities on campus. Companies featured include award-winning Plasticell, inward investor Aglaris and SBC alumnus Avacta Life Sciences.

Also in the report, SBC’s founder stakeholders GSK, Wellcome and BEIS/Innovate UK highlight the incubator’s impact.

‘Since being established five years ago, the Stevenage Bioscience Catalyst and the many scientists involved have created a vibrant scientific community at Stevenage, which has been a key part of a growing open innovation network.’, according to GSK.

‘Stevenage Bioscience Catalyst offers the collaborative environment essential for innovator-entrepreneurs to transform discoveries into treatments and products to improve our lives.’,Wellcome notes.

‘Stevenage Bioscience Catalyst has proven to be an exciting scientific and commercially successful world class open innovation pharma campus.’, says Innovate UK.

Ian Tomlinson, Independent Chairman of SBC, said, ‘With its diverse range of case studies and comment, ‘Five Years of Innovation with Impact‘ highlights the ways in which SBC has worked to catalyse innovation in the UK. In delivering on the vision of our stakeholders, whom we thank for their invaluable support, SBC has created a strong platform and community from which we will continue to collaborate to improve healthcare. The announcement last week of £12m of Government funding for increased capacity at the Cell and Gene Therapy Catapult Manufacturing Centre also recognises the potential of the campus and will be an important driver of its future growth.’



For more information, please contact:

Stevenage Bioscience Catalyst

Miranda Knaggs, Interim CEO                                                          +44(0)1438 906906

Emma Palmer Foster, Strategic Communications Consultant          +44(0)7880 787185


Notes for Editors

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst (SBC) opened as the UK’s first open innovation biomedical campus in 2012, and combines a unique blend of infrastructure and virtual networks to drive collaboration. Backed by a novel partnership between Government,GlaxoSmithKline and Wellcome, the remit was, and remains, to catalyse innovation for patient benefit in a phased development. SBC has a strong commitment to companies that focus on high quality science and share its vision, and its development of activity clusters and direct access to the expertise of a major pharmaceutical company are among its unique characteristics. There is start-up and grow-on space for companies, plus a commercially focused management team viewed as a leader in UK incubation. With Phase 1 at capacity, the next phase is in development for the continuation of the collaborative vision. Co-located with GlaxoSmithKline in Stevenage, Stevenage Bioscience Catalyst is located close to both London and Cambridge. For more information, please go to Follow us on twitter @SteBioCat

About Stevenage Bioscience Catalyst’s stakeholders

Stevenage Bioscience Catalyst’s stakeholders are GlaxoSmithKline (, Wellcome (, the Department for Business, Energy and Industrial Strategy (; formerly the Department for Business, Innovation and Skills), and Innovate UK (formerly the Technology Strategy Board;